Malik Eid Juweid
University of Jordan · 184 works · 12,942 citations · h-index 39
Top works
- Revised Response Criteria for Malignant Lymphoma
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
- Positron-Emission Tomography and Assessment of Cancer Therapy
- Response Assessment of Aggressive Non-Hodgkin’s Lymphoma by Integrated International Workshop Criteria and Fluorine-18–Fluorodeoxyglucose Positron Emission Tomography
- Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats.
- Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
- Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier.
- The role of FDG-PET scans in patients with lymphoma
- Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.
- Role of Positron Emission Tomography in Lymphoma
- Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
- Epidemiology and Outcome of Glioblastoma
- Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
- Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion.
- Molecular Imaging of Proliferation in Malignant Lymphoma
- Radioimmunotherapy of B-cell non-Hodgkin's lymphoma: from clinical trials to clinical practice.
- Pharmacokinetics, dosimetry, and initial therapeutic results with 131I- and (111)In-/90Y-labeled humanized LL2 anti-CD22 monoclonal antibody in patients with relapsed, refractory non-Hodgkin's lymphoma.
- Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023
- Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.
- Improvement of Early 18F-FDG PET Interpretation in Diffuse Large B-Cell Lymphoma: Importance of the Reference Background